Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT Articles uri icon

authors

  • Jimenez Ubieto, Ana
  • Poza, Maria
  • Martin Muñoz, Alejandro
  • Ruiz Heredia, Yanira
  • Dorado, Sara
  • Figaredo, Gloria
  • Rosa Rosa, Juan Manuel
  • Rodriguez, Antonia
  • Barcena, Carmen
  • Navamuel, Laura Parrilla
  • Carrillo, Jaime
  • Sanchez, Ricardo
  • Rufian, Laura
  • Juarez, Alexandra
  • Rodriguez, Margarita
  • Wang, Chongwu
  • TOLEDO HERAS, MARIA PAULA DE
  • Grande, Carlos
  • Mollejo, Manuela
  • Casado, Luis Felipe
  • Calbacho, Maria
  • Baumann, Tycho
  • Rapado, Inmaculada
  • Gallardo, Miguel
  • Sarandeses, Pilar
  • Ayala, Rosa
  • Martinez Lopez, Joaquin
  • Barrio, Santiago

publication date

  • January 2023

start page

  • 659

end page

  • 669

issue

  • 3

volume

  • 37

International Standard Serial Number (ISSN)

  • 0887-6924

Electronic International Standard Serial Number (EISSN)

  • 1476-5551

abstract

  • In the present study, we screened 84 Follicular Lymphoma patients for somatic mutations suitable as liquid biopsy MRD biomarkers using a targeted next-generation sequencing (NGS) panel. We found trackable mutations in 95% of the lymph node samples and 80% of the liquid biopsy baseline samples. Then, we used an ultra-deep sequencing approach with 2 · 10−4 sensitivity (LiqBio-MRD) to track those mutations on 151 follow-up liquid biopsy samples from 54 treated patients. Positive LiqBio-MRD at first-line therapy correlated with a higher risk of progression both at the interim evaluation (HRINT 11.0, 95% CI 2.10–57.7, p = 0.005) and at the end of treatment (HREOT, HR 19.1, 95% CI 4.10–89.4, p 

subjects

  • Computer Science
  • Medicine